Expiration date: 01/2025

Tablet, coated


1 tablet coated liner contains the active substance of Trimetazidine dihydrochloride 20 mg


30 or 60 PCs.

Pharmacological action

Trimetazidine antihypoxic agent. It has antianginal, antihypoxic effects. Directly affecting cardiomyocytes and neurons in the brain, optimizing their metabolism and function. Cytoprotective effect due to higher energy potential, activated oxidative, decarboxy profiling and rationalization of consumption of oxygen (increased aerobic glikoliza and blockade oxidation of fatty acids). Supports myocardial contractility, prevents a decrease in intracellular ATP content and FOS-tocreatinine. In conditions of acidosis normalizes the functioning of membrane ion channels, prevents accumulation of calcium and sodium in cardiomyo-zitah. normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphates, caused by myocardial ischemia and reperfusion. Prevents the damaging action of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the zone of ischemia, increases the duration of the electric potential, reduces the release of creatine kinase from the cells and the severity of ischemic myocardial damage.

When strokes reduces the frequency of attacks (reduced consumption of nitrate), through 2 week of treatment increases tolerance to physical activity, reduced variations in blood pressure. Improves hearing and results of vestibular tests in patients, reduces dizziness and tinnitus.

When vascular pathology eye restores functional activity retina.


  • Coronary heart disease: prevention of angina (in combination therapy):
  • Chorioretinal vascular disorders
  • Vertigo of vascular origin
  • Cochleo-vestibular disorders ischemic nature (tinnitus, hearing loss).


  • Hypersensitivity to any component of the drug,
  • Renal insufficiency (creatinine clearance below 15 ml/min),
  • Expressed violations of the liver,
  • Pregnancy


The age of 18 years (efficacy and safety not established).

Method of application and doses

Inside, during a meal.

The recommended dosing regimen of 2-3 tablets (40-60 mg) per day in 2-3 reception. The course of treatment for the advice of a doctor.

Side effects

The frequency of side effects noted when taking of Trimetazidine in the following gradation: very often (more 1/10), often (more 1/100, less than 1/10), uncommon (more than 1/1000, less than 1/100), rare (more 1/10000, less than 1/1000), very rarely (less 1/10000), including individual messages. 

From the digestive system: 

Frequent: abdominal pain, diarrhea, dyspepsia, nausea, vomiting. 

General disorders: 

Frequent: asthenia. 

From the Central nervous system: 

Frequent: dizziness, headache. 

Very rare: extrapyramidal disorder (tremor, rigidity, akinesia), reversible after discontinuation of the drug. 

From the skin: 

Frequent: skin rash, itching, hives. 

From the side of cardiovascular system: 

Rare: orthostatic hypotension, "tides" of blood to the skin.

Special instructions

The drug is not for relief of angina attacks, an initial course of therapy of stable angina or myocardial infarction. 

In the case of angina should be reviewed and adapted treatment.

Be careful when driving and occupation of other potentially hazardous activities, require high concentration and psychomotor speed reactions.


Data on cases of overdose is limited. In case of overdose should be symptomatic therapy.

Storage conditions

In a dry, protected from light place at temperature not exceeding 25°C. Keep out of the reach of children.

Shelf life

2 years.